Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
British Journal of Nursing (Mark Allen Publishing)|May 26, 2017
Imbruvica®▾(ibrutinib) patient support programme for chronic lymphocytic leukaemia and mantle cell lymphomaVidhya Murthy, Susan Weaving, Shankara Paneesha
Ejhaem|August 19, 2024
Extramedullary chronic phase chronic myeloid leukaemia (CML) involving the central nervous system: A case reportAkshay Deshpande, Dina Osman, Vidhya Murthy, et al.
Clinical Case Reports|October 29, 2015
Sclerosing angiomatoid nodular transformation of the spleenVidhya Murthy, Ben Miller, Emmanuel M Nikolousis, et al.
Polish Journal of Pathology : Official Journal of the Polish Society of Pathologists|December 5, 2018
Fatal systemic angiomatosis with widespread sclerotic skeletal changes, diagnosed with the aid of a bone marrow biopsy: the lymphatics enter the bone marrowZbigniew Rudzki, Richard Lovell, Ben Miller, et al.
Cell Transplantation|August 19, 2020
Autoimmune Cytopenias Developing Late Post Alemtuzumab-Based Allogeneic Stem Cell Transplantation: Presentation of Short Case Series from a Transplant CenterRebecca Lloyd, Emmanouil Nikolousis, Bhuvan Kishore, et al.
Leukemia Research Reports|July 3, 2020
First case of near haploid philadelphia negative B-Cell acute lymphoblastic leukaemia relapsing as acute myeloid leukemia following allogeneic hematopoietic stem cell transplantationClaire Horgan, Charalampos Kartsios, Emmanouil Nikolousis, et al.
Case Reports in Hematology|January 29, 2021
Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy AlterationsMaria Kaparou, Zbigniew Rudzki, Hannah Giles, et al.
Blood|March 29, 2020
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trialAndrew H Wei, Pau Montesinos, Vladimir Ivanov, et al.
Blood Cancer Journal|October 2, 2021
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Blood Advances|December 1, 2023
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AMLCarlos Jimenez-Chillon, Jad Othman, David Taussig, et al.
Pageof 2